Concepts (62)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 3 | 2024 | 705 | 1.520 |
Why?
|
| Elephantiasis | 1 | 2022 | 4 | 0.830 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2022 | 16 | 0.820 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2022 | 86 | 0.800 |
Why?
|
| Arm | 1 | 2022 | 139 | 0.790 |
Why?
|
| Neurofibromatosis 1 | 1 | 2022 | 159 | 0.730 |
Why?
|
| Edema | 1 | 2022 | 262 | 0.730 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 151 | 0.630 |
Why?
|
| Gangliosides | 1 | 2019 | 98 | 0.610 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 464 | 0.580 |
Why?
|
| Immunity, Innate | 1 | 2019 | 699 | 0.500 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1335 | 0.350 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 4481 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5408 | 0.250 |
Why?
|
| Immunotherapy | 1 | 2019 | 3557 | 0.250 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2024 | 155 | 0.220 |
Why?
|
| Spinal Cord Compression | 1 | 2024 | 167 | 0.220 |
Why?
|
| Bloom Syndrome | 1 | 2021 | 10 | 0.190 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 10708 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 382 | 0.170 |
Why?
|
| Dyspnea | 1 | 2022 | 420 | 0.170 |
Why?
|
| Spinal Neoplasms | 1 | 2024 | 670 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2022 | 437 | 0.160 |
Why?
|
| Mexican Americans | 1 | 2021 | 331 | 0.160 |
Why?
|
| Pathology, Molecular | 1 | 2019 | 124 | 0.150 |
Why?
|
| Infant | 2 | 2024 | 13999 | 0.150 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 342 | 0.150 |
Why?
|
| Immunologic Memory | 1 | 2019 | 380 | 0.150 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 797 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 2313 | 0.140 |
Why?
|
| Risk | 1 | 2019 | 1939 | 0.120 |
Why?
|
| Female | 5 | 2024 | 148940 | 0.120 |
Why?
|
| Child | 3 | 2024 | 30559 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2022 | 4831 | 0.110 |
Why?
|
| Proteomics | 1 | 2020 | 1427 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 5759 | 0.100 |
Why?
|
| Cytokines | 1 | 2019 | 2825 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2024 | 17061 | 0.090 |
Why?
|
| Humans | 7 | 2024 | 270740 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2024 | 13414 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2399 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 7655 | 0.080 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3035 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 2903 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7381 | 0.070 |
Why?
|
| Male | 3 | 2024 | 128315 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 14849 | 0.060 |
Why?
|
| Adolescent | 1 | 2024 | 32767 | 0.060 |
Why?
|
| Mutation | 1 | 2021 | 15912 | 0.050 |
Why?
|
| RecQ Helicases | 1 | 2021 | 95 | 0.040 |
Why?
|
| Mexico | 1 | 2021 | 275 | 0.040 |
Why?
|
| Homozygote | 1 | 2021 | 772 | 0.040 |
Why?
|
| Leucine | 1 | 2020 | 380 | 0.040 |
Why?
|
| Mice | 1 | 2019 | 35600 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 387 | 0.040 |
Why?
|
| Pedigree | 1 | 2021 | 2042 | 0.030 |
Why?
|
| Animals | 1 | 2019 | 61956 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 2057 | 0.030 |
Why?
|
| Alleles | 1 | 2021 | 2600 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 1424 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 4644 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 5776 | 0.020 |
Why?
|